Extended-spectrum β-lactamase-producing Gram-negative pathogens in community-acquired urinary tract infections: an increasing challenge for antimicrobial therapy.
about
Ready for a world without antibiotics? The Pensières Antibiotic Resistance Call to Action.Urinary tract infections in older women: a clinical reviewAn update on the management of urinary tract infections in the era of antimicrobial resistance.Detection of CTX-M-15 beta-lactamases in Enterobacteriaceae causing hospital- and community-acquired urinary tract infections as early as 2004, in Dar es Salaam, Tanzania.Antimicrobial susceptibility, risk factors and prevalence of bla cefotaximase, temoneira, and sulfhydryl variable genes among Escherichia coli in community-acquired pediatric urinary tract infectionHigh prevalence of multidrug resistance in bacterial uropathogens from Kathmandu, NepalRisk factors for bacteriuria with carbapenem-resistant Klebsiella pneumoniae and its impact on mortality: a case-control study.Extended spectrum beta-lactamase-producing Enterobacteriaceae in international travelers and non-travelers in New York CityEpidemiology and risk factors of community onset infections caused by extended-spectrum β-lactamase-producing Escherichia coli strains.Activity of Fosfomycin against Extended-Spectrum-β-Lactamase-Producing Uropathogens in Patients in the Community and Hospitalized PatientsFrequency, Antimicrobial Resistance and Genetic Diversity of Klebsiella pneumoniae in Food Samples.Oral fosfomycin for treatment of urinary tract infection: a retrospective cohort study.Perceptions and behaviours of infectious diseases physicians when managing urinary tract infections due to MDR organismsIn Vitro Activity of Oral Cephalosporins (Cefprozil and Cefixime) Against Ciprofloxacin-Resistant Enterobacteriaceae from Community-Acquired Urinary-Tract Infections.Access to antibiotics: a safety and equity challenge for the next decade.Alternative approaches to conventional treatment of acute uncomplicated urinary tract infection in women.Community-Onset Extended-Spectrum β-Lactamase-Producing Enterobacteriaceae Invasive Infections in Children in a University Hospital in France.Extended-spectrum ß-Lactamase-producing Enterobacteriaceae as a Common Cause of Urinary Tract Infections in Sri LankaEmerging resistance problems and future perspectives in pharmacotherapy for complicated urinary tract infections.Pyelonephritis: what are the present day causative organisms and antibiotic susceptibilities?Setting up an outpatient parenteral antimicrobial therapy (OPAT) unit in Switzerland: review of the first 18 months of activity.Novel inhibitors of the methicillin-resistant Staphylococcus aureus (MRSA)-pyruvate kinase.Changing epidemiology of infections due to extended spectrum beta-lactamase producing bacteria.First initial community-acquired meningitis due to extended-spectrum beta-lactamase producing Escherichia coli complicated with multiple aortic mycotic aneurysms.Clinical Management of an Increasing Threat: Outpatient Urinary Tract Infections Due to Multidrug-Resistant Uropathogens.The quest for the best metric of antibiotic use and its correlation with the emergence of fluoroquinolone resistance in children.Distribution of ESBL-producing enterobacteria associated to community-acquired monomicrobial urinary tract infections and antimicrobial susceptibility trends over a 9-year period.Quantification of bacterial uropathogens in preclinical samples using real-time PCR assays.Piperacillin-tazobactam as alternative to carbapenems for ICU patients.The effect of inappropriate therapy on bacteremia by ESBL-producing bacteria.Multi-drug-resistant Gram-negative bacteria causing urinary tract infections: a review.A one-year prospective study on the antibiotic resistance of E. coli strains isolated in urinary specimens of children hospitalized at the University Pediatric Medical Center in Novi Sad, Serbia.Prevalence, risk factors and microorganisms of urinary tract infections in patients with type 2 diabetes mellitus: a retrospective study in China.An infectious disease and pharmacokinetic perspective on oral antibiotic treatment of uncomplicated urinary tract infections due to multidrug-resistant Gram-negative uropathogens: the importance of urinary antibiotic concentrations and urinary pH.Antimicrobial photodynamic therapy mediated by methylene blue and potassium iodide to treat urinary tract infection in a female rat model.Clinical characteristics of community-acquired acute pyelonephritis caused by ESBL-producing pathogens in South Korea.Editorial commentary: extended-spectrum β-lactamase-producing escherichia coli in the united states: time to rethink empirical treatment for suspected E. coli infections?Risk factors for non-Escherichia coli community-acquired bacteriuria.
P2860
Q21195823-65D2A95F-9747-4A81-A639-B0AB2CE48FE2Q27002570-CD6631FC-57E4-48B1-8137-A093059D518AQ30244815-3B0D0AA4-1124-4DB6-8B43-53E781B1EC5CQ33568164-0759043D-7D50-4563-8F11-92B22A526665Q33868914-81C509A9-41A8-4268-AC5A-72770B832475Q34133230-4C6AB4E8-CF73-452B-800E-07D321B61E99Q34319838-1909AC1A-52EA-4C5B-BA64-3A1D8CD95AB9Q34428189-FA50BC29-D50E-44FD-B655-93FC40C9A657Q35689050-FB4EBDB9-02A4-45ED-A1C1-42C994BA4520Q35848981-2F29EF80-8256-466D-B18A-113CF825ED7CQ35989920-1864455E-9ACA-4073-B48A-6C9B03046B41Q36160749-BC642FCF-20C4-4D28-B2D8-3EF4F4B4ED77Q36298973-BD81BBC5-F62D-4D3D-9513-1E54A052ECD7Q36363226-B59B21E4-40A3-48C7-9A1A-07F4BA054644Q36689032-97E597B9-7E7B-412E-A3BC-09B604780D0BQ36754301-02120EFB-ED46-4297-AA38-B26A954613A2Q37205420-E3A35483-4BC3-45F6-A5A4-492197DDACACQ37306638-FCE1B26D-5E81-4E05-948B-E143A601983FQ38088261-DE39EFAA-8E56-493E-913D-67F368C944E0Q38097876-EA9C5176-F8E3-4523-8C56-EB592F368589Q38737317-60F84136-5949-408D-BCD6-A6AA13867EC1Q40876981-2B553D05-DBF3-49C0-A50A-964212EB31B2Q41773965-4B5D8C41-BEC2-46DB-8013-75C2AF0C9F5EQ41862417-0E811977-2ACB-4A9F-94F2-F1BCB8FD0933Q42102558-2FCEAF7B-2DD2-4C74-9C03-96A2032CB29CQ42215190-70565DF8-3D0B-4C17-B80F-67AD3CB5D226Q45073162-5786A20E-36F1-4D8D-87A9-7106B3AB609FQ45331678-72477B1E-BB0A-4A22-B14F-11D9E895F3C6Q45711115-EE0FB111-D381-4FE7-BE1A-6B68697E814AQ46108324-EE3922F4-9837-4438-8700-4E4D76366B45Q48357061-B6D58267-3FF2-44CE-A968-3AB004BAD8E4Q50796828-1ECBD2CB-7F50-47AA-9C94-CE2CD618EEDEQ53703561-F056F1BD-9B47-41E8-BB4F-0CA6184DBE75Q53798070-1AB31C43-DAEB-4BA9-971D-017FF9E951AEQ54217724-379063FA-D94A-46CB-9E7F-2D15369F9291Q54315149-5AD68B74-88CE-48C8-B84D-917E80822BA5Q54323558-CF42327B-375A-4E48-A16E-94ACE4DE9EF5Q54325953-9E694F4B-A0C4-497B-827B-37E21F49C803
P2860
Extended-spectrum β-lactamase-producing Gram-negative pathogens in community-acquired urinary tract infections: an increasing challenge for antimicrobial therapy.
description
2011 nî lūn-bûn
@nan
2011年の論文
@ja
2011年学术文章
@wuu
2011年学术文章
@zh
2011年学术文章
@zh-cn
2011年学术文章
@zh-hans
2011年学术文章
@zh-my
2011年学术文章
@zh-sg
2011年學術文章
@yue
2011年學術文章
@zh-hant
name
Extended-spectrum β-lactamase- ...... nge for antimicrobial therapy.
@en
Extended-spectrum β-lactamase- ...... nge for antimicrobial therapy.
@nl
type
label
Extended-spectrum β-lactamase- ...... nge for antimicrobial therapy.
@en
Extended-spectrum β-lactamase- ...... nge for antimicrobial therapy.
@nl
prefLabel
Extended-spectrum β-lactamase- ...... nge for antimicrobial therapy.
@en
Extended-spectrum β-lactamase- ...... nge for antimicrobial therapy.
@nl
P2093
P2860
P1433
P1476
Extended-spectrum β-lactamase- ...... nge for antimicrobial therapy.
@en
P2093
P2860
P2888
P304
P356
10.1007/S15010-011-0132-6
P577
2011-06-25T00:00:00Z